Spots Global Cancer Trial Database for Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Stereotactic Ablative Radiation for Oligo-Progression of Urothelial Cancer
Official Title: A Phase II Trial of Stereotactic Ablative Radiation (SAbR) for Urothelial Cancer Patients With Progression While on Anti-PD-1/PD-L1 Immunotherapy
Study ID: NCT04131634
Conditions
Interventions
Study Description
Brief Summary: To evaluate the benefit of SAbR for oligo-progressive metastatic urothelial cancer.
Detailed Description: Oligo-progressive urothelial cancer with limited disease burden and progression on an anti-PD-1/L1 immune checkpoint inhibitor.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Aurelie Garant, Dallas, Texas, United States
Contact Details
Name: Aurelie Garant
Affiliation: University of Texas Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
